Document:

Exhibit 4.8

 

Form 51-102F3

MATERIAL CHANGE REPORT

 

		Item 1.	Name and Address of Reporting Issuer

 

Emerald Health Therapeutics, Inc. (the “Company”)

PO Box 24076, 4420 West Saanich Road

Victoria, British Columbia V8Z 7E7

 

		Item 2.	Date of Material Change

 

January 9, 2018

 

		Item 3.	News Release

 

A news release was disseminated on
January 9, 2018 through GlobeNewswire and subsequently filed on SEDAR.

 

		Item 4.	Summary of Material Changes

 

The Company announced that, on January
9, 2018, it closed its prospectus sale (the “Offering”) to a single Canadian institutional accredited investor (the
“Investor”) as announced on January 3, 2018. Pursuant to the Offering, the Company issued 3,000,000 units (the “Units”)
at a price per Unit of $5.00, for gross proceeds of $15,000,000.

 

		Item 5.	Full Description of Material Change

 

The Company announced that, on January
9, 2018, it closed its Offering with the Investor as announced on January 3, 2018. Pursuant to the Offering, the Company issued
3,000,000 Units at a price per Unit of $5.00, for gross proceeds of $15,000,000.

 

Each Unit consisted of one common
share of the Company and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the Investor to
acquire one common share of the Company (a “Warrant Share”) at a price of $6.00 per Warrant Share for a period of 36
months following the closing of the Offering. In the event that the closing sale price of the Company’s common shares (the
“Common Shares”) on the TSX Venture Exchange is greater than $8.00 per Common Share for a period of 10 consecutive
trading days at any time after the closing of the Offering, the Company may accelerate the expiry date of the Warrants by giving
notice to the Investor and in such case the Warrants will expire on the 30th day after the date on which such notice is given by
the Company.

 

The Company intends to use the net
proceeds of the Offering for its production and R&D-related growth plans, working capital and general corporate purposes.

 

The Units were offered by way of
a shelf prospectus supplement filed in all of the provinces of Canada, except Quebec, pursuant to National Instrument 44-101 -
Short Form Prospectus Distributions.

 

     

     

    

   

		Item 6.	Reliance on subsection 7.1(2) of National Instrument 51-102

 

Not applicable.

 

		Item 7.	Omitted Information

 

Not applicable.

 

		Item 8.	Executive Officer

 

For further information, please contact:

Chris Wagner

Chief Executive Officer

Telephone: 1.800.757.3536 ext.720

 

		Item 9.	Date of Report

 

January 15, 2018

 

    	 	- 2 -Exhibit 4.9

 

Form 51-102F3

MATERIAL CHANGE REPORT

 

		Item 1.	Name and Address of Reporting Issuer

 

Emerald Health Therapeutics, Inc. (the “Company”)

PO Box 24076, 4420 West Saanich Road

Victoria, British Columbia V8Z 7E7

 

		Item 2.	Date of Material Change

 

February 8, 2018 and February 14, 2018

 

		Item 3.	News Release

 

A news release was disseminated on
February 8, 2018 and February 14, 2018 through GlobeNewswire and subsequently filed on SEDAR.

 

		Item 4.	Summary of Material Changes

 

The Company announced that, on February
8, 2018, it entered into a binding term sheet with a single Canadian institutional accredited investor (the “Investor”)
under which the Investor agreed to purchase 3,000,000 units of the Company (the “Units”) at a price of $6.00 per Unit
for total gross proceeds of $18,000,000 (the “Offering”). The Investor also agreed to purchase from Emerald Health
Sciences Inc. (“Sciences”), a control person of the Company, 2,000,000 Common Shares held by Sciences at a price of
$6.00 per share (the “Secondary Sale”).

 

The Company announced that, on February
14, 2018, it closed the Offering. Pursuant to the Offering, the Company issued 3,000,000 Units at a price per Unit of $6.00, for
gross proceeds of $18,000,000.

 

		Item 5.	Full Description of Material Change

 

The Company announced that, on February
14, 2018, it closed its Offering with the Investor as announced on February 8, 2018. Pursuant to the Offering, the Company issued
3,000,000 Units at a price per Unit of $6.00 for gross proceeds of $18,000,000.

 

Each Unit consisted of one common
share of the Company and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the Investor to
acquire one common share of the Company (a “Warrant Share”) at a price of $7.00 per Warrant Share for a period of six
months following the closing of the Offering, subject to accelerated expiry provisions.

 

The Units were offered by way of
a shelf prospectus supplement filed in all of the provinces of Canada, except Quebec, pursuant to National Instrument 44-101 -
Short Form Prospectus Distributions.

 

The Company intends to use the net
proceeds of the Offering for its production and R&D-related growth plans, working capital and general corporate purposes.

 

     

     

    

 

In connection with the Offering,
the Investor also exercised 3,000,000 warrants of the Company. These warrants, issued by the Company to the Investor on January
9, 2018, were exercised at a price of $6.00 per Common Share.

 

The Secondary Sale closed concurrently
with the closing of the Offering.

 

		Item 6.	Reliance on subsection 7.1(2) of National Instrument 51-102

 

Not applicable.

 

		Item 7.	Omitted Information

 

Not applicable.

 

		Item 8.	Executive Officer

 

For further information, please contact:

Chris Wagner

Chief Executive Officer

Telephone: 1.800.757.3536 ext.720

 

		Item 9.	Date of Report

 

February 26, 2018

 

    	 	- 2 -Exhibit 4.10

 

Form 51-102F3

MATERIAL CHANGE REPORT

 

	Item 1.	Name and Address of Reporting Issuer
	 	 
	 	Emerald Health Therapeutics, Inc. (the “Company”)
	 	PO Box 24076, 4420 West Saanich Road
	 	Victoria, British Columbia V8Z 7E7
	 	 
	Item 2.	Date of Material Change
	 	 
		May 2, 2018
	 	 
	Item 3.	News Release 
	 	 
	 	A news release was disseminated on May 2, 2018 through GlobeNewswire and subsequently filed on SEDAR.
	 	 
	Item 4.	Summary of Material Changes
	 	 
	 	The Company announced that, on May 2, 2018, it acquired (the “Acquisition”) all of the issued and outstanding securities of 8611165 Canada Inc., an Access to Cannabis for Medical Purposes Regulations (ACMPR) Licensed Producer located in Saint-Eustache, Québec, and its affiliate 9353-8460 Québec Inc. (together, “Agro-Biotech”). Under the terms of the Acquisition, Emerald will pay an aggregate purchase price of $90 million to the shareholders of Agro-Biotech, half in cash and half in shares. One-half of the cash consideration was paid on closing and the remainder will be payable on May 1, 2019. All of the shares were issued upon closing, however, half of the shares will be held in escrow until May 1, 2019, pursuant to an escrow agreement.
	 	 
	Item 5.	Full Description of Material Change 
	 	 
	 	Please see attached news release dated May 2, 2018
	 	 
	Item 6.	Reliance on subsection 7.1(2) of National Instrument 51-102 
	 	 
	 	Not applicable.
	 	 
	Item 7.	Omitted Information
	 	 
	 	Not applicable.
	 	 
	Item 8.	Executive Officer
	 	 
	 	For further information, please contact:
	 	Chris Wagner
	 	Chief Executive Officer
	 	Telephone: 1.800.757.3536 ext.720

 

     

     

    

 

	Item 9.	Date of Report
	 	 
	 	May 11, 2018

 

    	 	- 2 -	 

     

    

 

 

 

Emerald
Health Therapeutics Acquires Cannabis Licensed Producer in Québec

 

New Emerald operation, one of only six
licensed producers in Québec, adds indoor growing capacity of

approximately 10,000 kg per annum

 

VICTORIA, British Columbia, May 02, 2018
— Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH) (OTCQX:EMHTF) (Frankfurt:TBD) announced today that
it has acquired (the “Acquisition”) all of the issued and outstanding securities of 8611165 Canada Inc., an Access
to Cannabis for Medical Purposes Regulations (ACMPR) Licensed Producer located in Saint -Eustache, Québec, and its affiliate
9353-8460 Québec Inc. (together, “Agro-Biotech”). Agro-Biotech’s assets include a Health Canada cultivation
license, land, and 75,000 sq. ft. purpose-built facility. The Acquisition enhances this local startup’s resources to serve
Québec consumers with high-quality cannabis products in the anticipated legalized adult-use market, and further strengthens
Emerald’s ability to market throughout eastern Canada and nationwide.

 

This indoor hydroponic growing facility,
which has access to very low-cost energy and water, will be capable of high-yielding production of Emerald’s unique cannabis
strains, several of which are currently being grown in Agro-Biotech’s facility. Agro-Biotech’s extensive experience
in cannabis cultivation complements Emerald’s downstream product development focus, which is backed by its depth of pharmaceutical
industry R&D and clinical development expertise, and extensive consumer packaged goods and alcohol beverage marketing experience.

 

Agro-Biotech has built out 20,000 sq. ft.
of this facility and expects to have 50,000 sq. ft. equipped for indoor cannabis cultivation by year end. Emerald intends to meet
the requirements for an ACMPR sales license for this facility before the end of August. This operation is estimated to have production
capacity of 3,000 kg of cannabis in 2018 and have full production capacity exceeding 10,000 kg following completion of the build-out
by year end.

 

With the anticipated introduction of legalized
recreational cannabis in Canada, Emerald’s acquisition of Agro-Biotech expands its capacity to meet increased consumer demand
in the second half of 2018. Emerald is currently also retrofitting its 50-percent owned 1.1 million square foot greenhouse in Delta,
BC, which has its cultivation license and is expected to have over 46,000 kg of production capacity by 2019 and more than 75,000
kilograms of growing capacity when the facility reaches full production. Emerald is also constructing a 500,000-square foot hybrid
indoor and greenhouse cannabis growing facility in Metro Vancouver.

 

“On behalf of the entire team, we
are extremely grateful to the city of Saint-Eustache, which has been a supportive and welcoming community, and we look forward
to increasing local employment and contributing to the area’s economy,” said Avtar Dhillon, MD, Executive Chairman
of Emerald. “Québec’s and the city’s affordable electricity and water will enable us to produce unique,
high quality cannabis at very low cost. We are excited to become part of an established presence in Québec that will allow
us to be highly responsive to customers in this province and beyond.”

 

“Agro-Biotech is one of only six
Licensed Producers in Québec, Canada’s second largest province with a population of over 8.4 million. Our experienced
and talented team collectively has over 60 years of cannabis growing and broad horticulture experience,” said Yan Dignard,
President, RPIC/QPIC, of Agro-Biotech. “We did this deal as we respect Emerald’s capabilities and look forward to working
with their team to build a strong and differentiated cannabis product line in Québec and across Canada.”

 

Under the terms of the Acquisition, Emerald
will pay an aggregate purchase price of $90 million to the shareholders of Agro-Biotech, half in cash and half in shares. One-half
of the cash consideration was paid on closing and the remainder will be payable on May 1, 2019. All of the shares were issued
upon closing, however, half of the shares will be held in escrow until May 1, 2019, pursuant to an escrow agreement.

 

     

     

    

 

About Emerald Health Therapeutics, Inc.

 

Emerald Health Therapeutics (TSXV:EMH)
(OTCQX:EMHTF) (Frankfurt:TBD) is a Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations and
produces and sells dried cannabis and cannabis oil for medical purposes. It is adding a 500,000 square foot greenhouse in Metro
Vancouver to serve the anticipated legal Canadian adult-use cannabis market starting in 2018. Emerald owns 50% of a joint venture
with Village Farms International, Inc. that is converting an existing 1.1 million square foot greenhouse in Delta, BC to grow cannabis.
Emerald’s team is highly experienced in life sciences, product development and large-scale agribusiness. Emerald Health Therapeutics
is part of the Emerald Health group, which includes multiple companies focused on developing cannabis and cannabinoid products
with potential wellness and medical benefits.

 

Please visit www.emeraldhealth.ca for more information
or contact:

 

Rob Hill, Chief Financial Officer

(800) 757 3536 Ext. #5

 

Ray Lagace, Investor Relations Manager

(800) 757 3536 Ext. #5

invest@emeraldhealth.ca

 

Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release.

 

Cautionary Note Regarding Forward-Looking
Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are
subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual
results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such
statements include legalization of non-medicinal cannabis; production capacity of various facilities; expansion of facilities;
obtaining a sales license for the Saint-Eustache facility; and anticipated production costs.

 

We cannot guarantee that any forward-looking
statement will materialize and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking
statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain
necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in
prices and costs of inputs; demand for labour; demand for products; as well as the risk factors described in the Company’s
annual information form and other regulatory filings. The forward-looking statements contained in this press release represent
our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about
management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated
operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes
no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required
by applicable law.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}]]